Mesa Laboratories (NasdaqGS:MLAB) 2025 Conference November 20, 2025 07:00 AM ET Company ParticipantsJohn Sakys - CFOGary Owens - CEOConference Call ParticipantsNone - AnalystGary OwensWhich will be highly attractive. Biopharmaceutical development did 17% growth in the quarter. This is where we do protein analytics to support clinical trials and is essentially an engineering tool for bioprocessing design. That was probably a little bit inflated in the quarter. The 6.4% we have done for the full year is proba ...